{"id":"NCT04648241","sponsor":"Pfizer","briefTitle":"Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older","officialTitle":"A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-18","primaryCompletion":"2022-02-21","completion":"2022-02-21","firstPosted":"2020-12-01","resultsPosted":"2023-11-22","lastUpdate":"2023-11-22"},"enrollment":165,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Tick-Borne Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"TBE vaccine 0.5 mL","otherNames":[]},{"type":"BIOLOGICAL","name":"TBE vaccine 0.25 mL","otherNames":[]}],"arms":[{"label":"â‰¥16 Years Old","type":"EXPERIMENTAL"},{"label":"1 to <16 Years Old","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.","primaryOutcome":{"measure":"Percentage of Seropositive Participants at 4 Weeks After Dose 3","timeFrame":"4 weeks after Dose 3","effectByArm":[{"arm":"Adults (>=16 Years Old)","deltaMin":98,"sd":null},{"arm":"Pediatric (1 to <16 Years Old)","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":["38614954"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B9371039"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Injection site pain (PAIN)","Fatigue (FATIGUE)","Headache (HEADACHE)","Diarrhoea (DIARRHEA)","Myalgia (MUSCLE PAIN)"]}}